| Entry |
|
| Name |
Mutation-activated HRAS to ERK signaling pathway
|
| Definition |
HRAS* -> RAF -> MEK -> ERK -> MSK1 -> MYC |
| Expanded |
3265v2 -> (369,673,5894) -> (5604,5605) -> (5594,5595) -> 9252 -> 4609 |
| Class |
|
| Type |
Variant
|
| Pathway |
|
| Disease |
|
| Gene |
| 3265 | HRAS; HRas proto-oncogene, GTPase |
| 369 | ARAF; A-Raf proto-oncogene, serine/threonine kinase |
| 673 | BRAF; B-Raf proto-oncogene, serine/threonine kinase |
| 5894 | RAF1; Raf-1 proto-oncogene, serine/threonine kinase |
| 5604 | MAP2K1; mitogen-activated protein kinase kinase 1 |
| 5605 | MAP2K2; mitogen-activated protein kinase kinase 2 |
| 5594 | MAPK1; mitogen-activated protein kinase 1 |
| 5595 | MAPK3; mitogen-activated protein kinase 3 |
| 9252 | RPS6KA5; ribosomal protein S6 kinase A5 |
| 4609 | MYC; MYC proto-oncogene, bHLH transcription factor |
|
| Variant |
|
| Reference |
|
| Authors |
Mitra AP, Datar RH, Cote RJ. |
| Title |
Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. |
| Journal |
|
| Reference |
|
| Authors |
Wolff EM, Liang G, Jones PA. |
| Title |
Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer. |
| Journal |
|
| LinkDB |
|